Loading…
← CockpitCompetitor Analysis › 6446.TW PharmaEssentia Corp.Open in the cockpit ↗

PharmaEssentia Corp.6446.TWCompetitor analysis, valuation and peers

Taiwan · TWD·Health Care›Pharmaceuticals: Major

Taiwan biopharma that developed and sells Besremi (ropeginterferon alfa-2b), a treatment for the blood cancer polycythemia vera.

≈ A small, single-franchise specialty biotechMomentum leader 92
Mkt cap
$15.0B
US dollars, full cap
Free float
89%
of shares outstanding
$/day
$129M
20-day average traded
Fwd P/E
31.9×
forward earnings
ROIC−WACC
+44.5 pp
WACC 7.5%
Hurdle
-71 pp
Req g minus delivered
Next earnings
104 days
2 Mar 2027
Close · TWDNT$1,245
1D-2.7%
1W-6.7%
1M0.0%
3M-17.0%
6M+67.2%
YTD+193.8%
1Y+177.3%
ATR %6.1%
52w lowhigh24.3% off high

What PharmaEssentia does

Taiwan biopharma that developed and sells Besremi (ropeginterferon alfa-2b), a treatment for the blood cancer polycythemia vera.

Earns almost entirely from one injectable drug for a rare blood cancer, so revenue depends on how many patients are started on it and how long they stay on treatment, plus insurer coverage. It launched the drug itself in the US after the 2021 FDA approval and uses partners in some other markets.

In one line: A small, single-franchise specialty biotech.

Products and services

  • Besremi (ropeginterferon alfa-2b) for polycythemia vera
  • Pipeline interferon-based therapies

Customers

  • Hematologists/oncologists
  • Health systems in US, Europe and Asia treating pol

Where it sits in the supply chain

  • Health care
  • Biopharmaceuticals
  • Specialty/rare-disease drug development…

What could go right

  • Besremi volume growth in US/EU/Asia
  • New indication approvals

What could go wrong

  • Single-product revenue concentration
  • Reimbursement/pricing pressure

Moat: narrow (IP / patents, regulatory licence). Patent-protected, FDA/EMA-approved biologic with limited direct alternatives for its indication.

Headquarters: Taipei, Taiwan · Founded: 2003

Named competitors

PharmaEssentia at a glance

Size PharmaEssentia (6446.TW) is a Taiwan Health Care company (Pharmaceuticals: Major) with a market value of $15.0B, the 37th largest of 648 Taiwan companies the cockpit tracks. Shares closed at NT$1,245 on 18 Nov 2026.

Performance Over six months the shares gained 67.2%, against +4.4% for the median peer and -3.4% for the Taiwan market (cap-weighted) — 2nd highest of 21 in its peer set.

Growth Revenue grew 78.2% over the last twelve months (peer median +14.7%); the operating margin is 40.4% (peer median 21.3%).

Valuation It trades at 31.9× forward earnings against a peer median of 24.1× (8th most expensive of 20).

Price implies For today's price to make sense, revenue must grow about 24% a year for seven years (Req g). Recent delivered growth is +95%, so the hurdle is -71 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 44.5 points above its cost of capital (7.5% WACC).

Next results Next results expected around 2 Mar 2027 (exchange calendar; dates can move).

Relative performance

10015020021 May 202621 Aug 202618 Nov 20266446.TW 171Peer median 105
Six months, rebased to 100: PharmaEssentia against the median of its 20 peers (local-currency closes).

PharmaEssentia financials

Reported figures in TWD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueNT$24.6BNT$15.6BNT$9.73BNT$5.11BNT$2.88B
Revenue growth—+61%+91%+77%—
Gross profitNT$22.5BNT$13.7BNT$8.31BNT$4.34BNT$1.95B
EBITDANT$10.4BNT$5.33BNT$2.10B-NT$1.64B-NT$1.80B
Net incomeNT$9.08BNT$5.05BNT$2.97B-NT$624M-NT$1.37B
Free cash flowNT$6.87BNT$3.37BNT$1.67B-NT$2.03B-NT$1.83B
Capital expenditureNT$3.58BNT$2.01BNT$932MNT$1.36BNT$321M
Total debtNT$1.11BNT$856MNT$965MNT$1.20BNT$1.57B

Quarterly statements and history in the cockpit →

PharmaEssentia competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+20%+40%+60%-10%0%+10%000538688506IPNORNAVJAZZSOBIEXELLAURUSLABSASND6990ZYDUSLIFEDRREDDY1177RECTORNTPHARM1801600436ALNY6446.TW6-month return →1-month return →
Up and to the right = strong over both horizons. PharmaEssentia is the large dot.

Fundamentals: revenue growth against valuation

0%+50%+100%0×500×1,000×000538IPNORNAVLAURUSLABSASND69904507DRREDDY1801600436ALNY6446.TWRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. PharmaEssentia is the large dot.

Capital: growth delivered against growth the price implies

0%+50%+100%+150%0%50%100%150%000538IPNORNAVLAURUSLABSASND6990DRREDDYTORNTPHARM1801600436ALNY6446.TWGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. PharmaEssentia is the large dot.

PharmaEssentia competitors and peer comparison

Head to head with its named competitors (6446.TW vs BMY vs NOVN.SW vs INCY)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
PharmaEssentia 6446.TW$15.0B+67%+78%40%31.9×23.7%
Bristol Myers Squibb BMY$122B+3%+4%33%9.2×-13.1%
Novartis NOVN.SW$285B+11%-4%30%17.5×1.6%
Incyte INCY$24.0B+21%+25%12%15.1×14.2%
Protagonist Therapeutics PTGX$8.30B+26%+164%59%1,532.5×17.5%
Takeda Pharmaceutical 4502.T$69.8B+30%+6%18%51.0×3.7%

How PharmaEssentia compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

PharmaEssentia against its 20 peers (data as of 18 Nov 2026)
Measure6446.TWPeer medianRank in peer set
1-month return0.0%+6.1%6th lowest of 21
6-month return+67.2%+4.4%2nd highest of 21
Distance from 52-week high-24.3%-6.8%7th lowest of 21
Revenue growth (TTM)+78.2%+14.7%2nd highest of 21
Operating margin40.4%21.3%highest of 21
Forward P/E31.9×24.1×8th most expensive of 20
Growth the price implies (Req g, 7 yrs)23.7%0.8%7th most demanding of 19
Growth delivered (Del g)+94.8%+12.3%2nd highest of 19
Hurdle (Req g minus delivered)-71.1 pp-11.2 pp2nd least demanding of 19
ROIC minus cost of capital+44.5 pp+7.2 pp3rd highest of 21
EV / EBITDA44.5×17.1×3rd most expensive of 17
Net debt / EBITDA-2.5×0.3×2nd least indebted of 17

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
PharmaEssentia 6446.TWTaiwan$15.0B+67%+78%40%31.9×23.7%+94.8%
Yunnan Baiyao 000538.SZChina$15.0B+11%+5%11%18.3×-0.2%+4.7%
Sichuan Biokin Pharmaceutical 688506.SSChina$14.9B-7%+14%-43%n/an/an/a
Ipsen IPN.PAFrance$14.8B+1%+14%30%10.8×-6.7%+7.2%
Orion ORNAV.HEFinland$15.7B+41%+34%38%23.6×-6.2%+11.7%
Jazz Pharmaceuticals Public JAZZUnited States$15.9B+4%+13%25%9.3×-2.8%+12.5%
Swedish Orphan Biovitrum SOBI.STSweden$16.1B+6%+15%30%24.1×-2.1%+13.1%
Exelixis EXELUnited States$16.7B+37%+9%40%17.7×-3.8%+18.6%
Laurus Labs LAURUSLABS.NSIndia$13.4B+73%+23%24%76.4×51.2%+7.3%
Ascendis Pharma A/S ASNDUnited States$16.9B+12%+94%18%28.0×19.2%+152.4%
Sichuan Kelun-Biotech Biopharmaceutical 6990.HKHong Kong$13.0B-1%+44%-38%1,176.1×55.3%+33.6%
Zydus Lifesciences ZYDUSLIFE.NSIndia$12.8B+18%+24%17%30.0×n/an/a
Shionogi & 4507.TJapan$17.6B+3%+46%29%11.8×0.2%+11.0%
Dr. Reddy's Laboratories DRREDDY.NSIndia$12.5B+5%-4%9%32.0×30.7%+12.1%
Sbp 1177.HKHong Kong$12.2B+5%+15%30%17.5×-5.7%+5.4%
Recordati REC.MIItaly$12.0B+3%+8%30%16.6×1.1%+12.6%
Torrent Pharmaceuticals TORNTPHARM.NSIndia$18.8B+3%+42%22%70.2×37.6%+11.3%
Innovent Biologics 1801.HKHong Kong$18.9B+4%+43%17%52.3×11.6%+26.8%
Zhangzhou Pientzehuang Pharmaceutical 600436.SSChina$11.6B-4%-19%19%40.7×24.9%+6.8%
Mankind Pharma MANKIND.NSIndia$11.6B+5%+13%21%44.4×28.6%+18.1%
Alnylam Pharmaceuticals ALNYUnited States$20.0B-50%+56%20%21.2×0.5%+49.8%

Questions

Who are PharmaEssentia's main competitors?
Named competitors: Bristol Myers Squibb (BMY), Novartis (NOVN.SW), AOP Health (private or unlisted), Incyte (INCY), Protagonist Therapeutics (PTGX), Takeda Pharmaceutical (4502.T). The cockpit's measured peer set (industry) also includes Yunnan Baiyao (000538.SZ), Sichuan Biokin Pharmaceutical (688506.SS), Ipsen (IPN.PA), Orion (ORNAV.HE), Jazz Pharmaceuticals Public (JAZZ), Swedish Orphan Biovitrum (SOBI.ST).
Is PharmaEssentia expensive compared with its peers?
On forward p/e it trades at 31.9× against a peer median of 24.1×, 8th most expensive of 20 in its peer set. For today's price to make sense, revenue must grow about 24% a year for seven years (Req g). Recent delivered growth is +95%, so the hurdle is -71 pp: the price already allows for a slowdown.
How has PharmaEssentia stock performed?
Over six months to 18 Nov 2026 the shares returned +67.2% against +4.4% for the median peer; over one year +177.3%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.